This is a randomized, placebo controlled, double-blind, 2-way crossover study to assess the effect of intensive UA lowering therapy with RDEA3170, febuxostat, and dapagliflozin on urinary excretion of UA, in asymptomatic hyperuricemic patients. Twenty-four asymptomatic hyperuricemic patients aged 18 to 65 years (inclusive) will be enrolled into this study at 2 study centers.